**Meirong Liang, M.D.**

Visiting Scholar in Dr. Chien’s Lab from March 28, 2024

Department of Biochemistry and Molecular Medicine, UC Davis Health.

Chief Doctor, Department of Oncology

Jiangxi Maternal and Child Health Hospital

Nanchang, 330006 Jiangxi Province, China

**EDUCATION**

**Nanchang University**, Nanchang, China

*Doctor of Medicine in Gynecology,* 2014-2019

**Nanchang University**, Nanchang, China

*Master of Medicine in Gynecologic Oncology,* 2005-2008

**Jiangxi Medical College**, Nanchang, China

*Bachelor of Medicine in Clinical Medicine,* 2000-2005

**HOSPITAL APPOINTMENT**

**Jiangxi Maternal and Child Health Hospital**, Nanchang, China

*Chief Doctor* (2023.01-Present), *Associate Chief Doctor* (2014.03-2022.12), Department of Oncology

 Clinical Expertise: Specialize in surgical treatments (laparoscopic minimally invasive surgery and open surgery), radiotherapy, chemotherapy, and comprehensive treatment for gynecologic cancers, including ovarian cancer, cervical cancer, endometrial cancer, etc., especially recurrent gynecological malignant tumors.

 Research Skills: Cell culture, establishment of primary uterine stromal cells and cervical adenocarcinoma cisplatin-resistant cell lines (HeLa/DDP), gene probe design, RT-PCR amplification and sequencing,

Western blot, plasmid construction, detection of biological characteristics of HeLa/DDP, etc.

**TRAINING**

**Cancer Hospital of the University of Chinese Academy of Sciences**, China (2021.09-2022.02)

 Trained in *Gynecological Oncology Surgery*, including ultra-radical surgery for ovarian cancer, secondary cytoreductive surgery in recurrent ovarian cancer, etc., as well as perioperative management.

**AFFILIATIONS**

 Youth Committee Member, The 5th Gynecological Oncology Branch of Chinese Medical Association (2019-)

 Youth Committee Member, The 10th Obstetrics and Gynecology Committee of Chinese Association of Integrative Medicine (2020-)

 Committee Member of Academic Branch, The Obstetrics and Gynecology Committee of Chinese Association of Integrative Medicine (2019-)

 Committee Member, The 1st Collaborative Group on Gynecological Tumor Markers, Tumor Marker Committee of Chinese Anti-Cancer Association (2021-)

 Standing Committee Member/Deputy Secretary General, The 6th Gynecological Oncology Committee of Jiangxi Anti-Cancer Association (2021-)

 Standing Committee Member of The 1st Youth Committee, Tumor-Targeted Therapy Committee of Jiangxi Anti-Cancer Association (2020-)

 Committee Member, The 1st Oncology Branch of Jiangxi Medical Association (2023-)

 Member of The 1st Committee, Minimally Invasive Obstetrics and Gynecology Branch of Jiangxi Provincial Health Association (2020-)

**RESEARCH PROJECTS**

1. **A prospective controlled study on refined hierarchical management of FIGO stage IIIC1r cervical cancer based on tumor size.** (2021.1-2023.12)

Jiangxi Province Key R&D Program Western Clinical Medicine Project (20203BBGL73137) Role: PI

2. **An open randomized controlled study of bevacizumab combined with albumin-bound paclitaxel /irinotecan as second-line therapy for persistent, metastatic, and recurrent cervical cancer**

(2021.1-2023.12)

General Science and Technology Plan of Jiangxi Provincial Department of Health (202110095) Role: PI

**3. Molecular mechanism of estrogen receptor-mediated MBD2 regulating pS2/TFF1-EFGR signaling axis in human uterine leiomyoma cells** (2018.1-2021.12)

Jiangxi Provincial Department of Science and Technology (20181BBG78016)

Role: PI

**4. A new modified laparoscopic type C1 hysterectomy---based on the anatomic landmark of the deep uterine vein and its branches** (2018.1-2020.12)

Grassroots Health Appropriate Technology "Spark Promotion Plan" Project of Jiangxi Province (20198025) Role: PI

5. **The molecular mechanism of the methylation status of MBD2 promoter region in uterine fibroids and its downregulated expression in promoting the development of uterine fibroids** (2018.1-2020.12)

General Science and Technology Plan of Jiangxi Provincial Health and Family Planning Commission (20185391)

Role: PI

**6. Molecular mechanism of ERK1/2-p16 (INK4a) signaling pathway in cisplatin resistance in cervical adenocarcinoma** (2013.1-2016.12)

National Natural Science Foundation of China (81260383)

Role: Co-Investigator (2nd)

**PUBLICATIONS**

1. Zhang JW, Wang YN, Zhong ML, **Liang MR**\*. Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma. *Cell Div.* 2023 Sep 24;18(1):15. (\*corresponding author)

2. Xiao Y, **Liang MR**, Liu CC, Wang YN, Zeng Y, et al. Overexpression of P16 reversed the MDR1-mediated DDP resistance in the cervical adenocarcinoma by activating the ERK1/2 signaling pathway. *Cell Div*. 2019 Jul 6;14:6.

3. **Liang MR**, Zeng Y, Zeng SY, Zhang JW, et al. The Expression of MBD6 Is Associated with Tumor Size in Uterine Leiomyomas. *Genet Test Mol Biomarkers*. 2019 Aug;23(8):523-532.

4. Jiang W, **Liang M**, Han D, Liu H, et al. A Modification of Laparoscopic Type C1 Hysterectomy to Reduce Postoperative Bladder Dysfunction: A Retrospective Study. *J Invest Surg.* 2019 Apr;32(3):272-280.

5. **Liang MR**, Zeng SY, Jiang W, Li L, et al. Treatment and outcome of Stage I A1 squamous carcinoma of the cervix: a clinicopathologic study of 346 cases. *European Journal of Gynaecological Oncology*. 2016, 37(6): 775-780.

6. **MR Liang,** DX Han, W Jiang, H Liu, et al. Laparoscopic type C1 hysterectomy based on the anatomic landmark of the uterus deep vein and its branches for cervical cancer. *Chinese Journal of Oncology*. 2018, 40(4):288-294.

7. **MR Liang,** Y Zeng, SY Zeng, et al. Overexpression of MBD2 on biological function of uterine leiomyoma cell and promoter methylation of MBD2 in human uterine leiomyoma. *Chinese Journal of Clinical Obstetrics and Gynecology.* 2019, (6): 519-522.

8. ML Zhong, **MR Liang,** W Jiang, et al. The indication and surgery scope for laparoscopic extraperitoneal lymphadenectomy in locally advanced cervical cancer. *Chinese Journal of Oncology.* 2019, 41(4):303-308.

9. J Zhou, **MR Liang**. Comparison of short-term and long-term curative effects of different chemotherapy regimens in treatment of patients with locally advanced cervical adenocarcinoma. *Maternal and Child Health Care of China*. 2017, 32(4):668-670.

10. SY Zeng, **MR Liang,** LY Li, L Li, et al. Application of transvaginal external fascia trachelectomy in the treatment of CIN and micro-invasive cervical cancer. *Chinese Journal of Oncology*. 2013, 35(7):543-546.

11. **MR Liang,** SY Zeng, SL Wang, ML Zhong, et al The value of combined serum human epididymis secretory protein 4 and CA125 assay in differential diagnosis of ovarian benign and malignant tumor. *Chinese Journal of Clinicians (Electronic Edition).* 2013, (20):9148-9152.

12. SY Zeng, **MR Liang,** LY Li, et al. The relation of serum squamous cell carcinoma antigen level and pelvic lymph node HPV 16/18 infection with prognosis of cervical squamous cell carcinoma. *Basic & Clinical Medicine*. 2012, 32(10):1167- 1170.

13. **MR Liang,** SY Zeng, LY Li, ML Zhong. Analysis of Transvaginal External Fascia Trachelectomy. *Chinese General Practice.* 2012, 15(20):2350-2353.

**PATENTS**

 **MR Liang**, SY Zeng, W Jiang, et al. Minimally invasive non-tumor bendable uterus traction grasping forceps. CN210811422U. (2020-06-23)

 **MR Liang**, SY Zeng, DX Han, et al. Novel binding clip of pug clamp. CN210811423U. (2020-06-23)